Extended Data Table 4 Post hoc, on-treatment safety analysis showing adverse events in women

From: Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial

  1. *Spironolactone versus usual care. Two-sided P-value. Level of significance = 0.05. †Fisher’s exact test. ‡Chi-squared test. All row and column headings are in bold format for clarity.
Back to article page